FOLH1 and posterior cortical atrophy: In addition, it should be noted that aberrant expression, and loss of PSMA expression have already been demonstrated in patients with mCRPC and in patients with neuroendocrine prostate cancer (NEPC), which could be factors related to the achieved spectrum of PSMA protein levels in a heterogeneous group of PCa patients [23,24].